Indirect MCL-1 suppression via CDK9 inhibitors (e.g., alvocidib) or translation modulators offers a tunable alternative, with a 2025 study showing synergy with venetoclax in MCL-1-dependent AML (Alvarado-Valero et al., 2025). This evidence concerns the gene CDK9 and acute myeloid leukemia.